Andrew Gogbashian
Overview
Explore the profile of Andrew Gogbashian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alizzi Z, Gogbashian A, Karteris E, Hall M
Cancer Imaging
. 2023 Jun;
23(1):62.
PMID: 37322564
Background: In patients with cancer, the current gold standard for assessing response to treatment involves measuring cancer lesions on computed tomography (CT) imaging. The percentage change in size of specific...
2.
Sharma A, Lakhani A, Ghosh-Ray S, Alam S, Padhani A, Gogbashian A, et al.
Anticancer Res
. 2023 Jan;
43(2):789-793.
PMID: 36697087
Background/aim: Treatment for advanced renal cell carcinoma (aRCC) comprises single agent or combinations of immune checkpoint inhibitors and/or anti-angiogenic agents. Pazopanib is a multitargeted anti-angiogenic tyrosine kinase inhibitor (TKI) approved...
3.
Sharma A, Morrison L, Milic M, Ghose A, Gogbashian A, Vasdev N, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291757
Background/Aim: The occurrence of germ cell tumour (GCT) in the elderly is rare, with scarce data available. The aim of this study was to understand the clinical outcomes of patients...
4.
Zahoor A, Swamy R, Gogbashian A, Sharma A
BMJ Case Rep
. 2022 Apr;
15(4).
PMID: 35459646
A man in his mid-70s presented with a lump in his left testicle. He had previously been treated for prostate cancer with radical radiotherapy. He was on treatment for hypertension...
5.
El-Taji O, Al-Mitwalli A, Malik F, Agarwal S, Gogbashian A, Hughes R, et al.
Transl Androl Urol
. 2021 Jul;
10(6):2427-2434.
PMID: 34295729
Background: Secondary neoplasms of the bladder account for 4.5% of all bladder neoplasms however there is limited literature reporting management and survival. This is the largest single centre series presented...
6.
Sharma A, Babra D, Joshi P, Hall M, Gogbashian A, Vasdev N, et al.
In Vivo
. 2020 Nov;
34(6):3675-3679.
PMID: 33144484
Background/aim: High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy...
7.
Kosmin M, Padhani A, Gogbashian A, Woolf D, Ah-See M, Ostler P, et al.
Radiology
. 2020 Oct;
297(3):622-629.
PMID: 33078998
Background CT and bone scintigraphy have limitations in evaluating systemic anticancer therapy (SACT) response in bone metastases from metastatic breast cancer (MBC). Purpose To evaluate whether whole-body MRI enables identification...
8.
Alifrangis C, Sharma A, Chowdhury S, Duncan S, Milic M, Gogbashian A, et al.
Eur J Cancer
. 2020 Oct;
164:105-113.
PMID: 33041185
Background: Radiotherapy and cisplatin-based combination chemotherapy are accepted standard-of-care treatments for metastatic seminoma with excellent survival outcomes but with established short- and long-term morbidity. Carboplatin monotherapy may be a less...
9.
Sharma A, Alifrangis C, Milic M, Hall M, Vasdev N, Wilson P, et al.
Anticancer Res
. 2019 Sep;
39(9):4911-4916.
PMID: 31519595
Background/aim: The occurrence of somatic transformation in germ cell tumour (GCT) is rare, with increased incidence in teratomatous tumours. The aim of this study was to understand the clinical outcomes...
10.
Woolf D, Li S, Detre S, Liu A, Gogbashian A, Simcock I, et al.
Biomark Cancer
. 2019 Jun;
11:1179299X19851513.
PMID: 31210736
Background: Tumour heterogeneity is considered an important mechanism of treatment failure. Imaging-based assessment of tumour heterogeneity is showing promise but the relationship between these mathematically derived measures and accepted 'gold...